GlassScriptPhysician profile
Garrick L Shreck
NPI 1043205651
$7,066.16
in general payments reported to CMS, 2019-2025
52 companies · $856 in 2025
The $856 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $659 · 2021: $1,624 · 2022: $987 · 2023: $1,131 · 2024: $1,046 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,033.23 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.49 | 2020-2025 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $844.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $602.39 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $420.94 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $383.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.76 | 2019-2024 | Jardiance |
| Amgen INC. | $319.00 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $287.10 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $269.70 | 2021-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $237.18 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $217.52 | 2020-2022 | |
| Novo Nordisk INC | $212.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.09 | 2019-2025 | Xifaxan |
| Corium, LLC | $155.99 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $151.30 | 2023-2025 | Aplenzin, Wellbutrin |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrick Shreck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.